Breaking News

MAHA is coming. Here's who's along for the ride

November 7, 2024
Hans Pennink/AP

Bird flu infections in farmworkers are going undetected, study shows

Blood samples taken from 115 farmworkers in Michigan and Colorado over the summer found evidence of a recent infection in eight individuals.

By Megan Molteni


STAT+ | AstraZeneca says China has detained a senior executive

The company believes Chinese authorities are probing allegations that two current and two former employees had illegally imported cancer drugs.

By Ed Silverman


STAT+ | Biotech and Donald Trump: A conversation about what comes next

STAT's Adam Feuerstein and Matthew Herrper talk about why the industry wants a strong, functioning FDA, and what Wall Street is saying.

By Adam Feuerstein



The "Make America Healthy Again" movement, led by Robert F. Kennedy Jr., top, includes a wide cast including, clockwise, Vani Hari, blogger, Sen. Ron Johnson, and Mark Hyman, a doctor entrepreneur.
Christine Kao/STAT; Photos: Getty

STAT+ | 'MAHA' is moving into Trump's White House. Here's who RFK Jr. could bring along for the ride 

Here are 10 influencers, entrepreneurs, and lawmakers who, with Robert F. Kennedy Jr., could shake up health care in the Trump administration

By Isabella Cueto


Opinion: Tattoo-less radiation treatment is the future of cancer care

The four to 12 freckle-size tattoos traditionally used to guide radiation therapy can come with a serious emotional toll.

By William Chun-Ying Chen and Louis Potters


Sarepta discontinues next-generation Duchenne drugs

Today's biotech news includes what biopharma leaders think of the new Trump era, Sarepta discontinuing next-gen Duchenne drugs, and more.

By Elaine Chen


Photo illustration: Christine Kao/STAT; Photos: Norstella, Parexel, Concert AI, Biophy

STAT+ | These 6 companies are using AI to streamline clinical trials for pharma

AI companies are predicting clinical trial outcomes or even building simulated control arms in place of participants taking a placebo

By Katie Palmer


A letter from the executive editor: A seminal moment for science journalism

We are at a unique moment in our country's history, when an understanding of the issues that STAT covers is more relevant than ever before.

By Rick Berke


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments